Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

Abstract Background Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’s mutanome, autologous tumor may be the best source of tumor-associated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas T. Amatruda, Carol Depriest
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018-03-01
Colecção:Journal for ImmunoTherapy of Cancer
Assuntos:
Metastatic melanoma
Patient-specific vaccines
Dendritic-cell vaccines
Tumor-cell vaccines
Autologous tumor cell lines
Acesso em linha:http://link.springer.com/article/10.1186/s40425-018-0330-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados